Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Nanoparticles Deliver One-Two Therapeutic Punch to Kill Tumor Cells

Polymer-caged nanobins (PCNs) that can undergo Cu(I)-catalyzed click reactions enable the combination of GdIII magnetic resonance imaging (MRI) contrast agents and an anticancer drug (gemcitabine, GMC) into a single theranostic platform (see picture). The resulting gadolinium(III)-conjugated, GMC-loaded PCNs (GdIII–PCNGMC) exhibit a significantly superior performance in r1 relaxivity, drug uptake, and pH-sensitive drug release. Credit Angewandte Chemie International Edition
Polymer-caged nanobins (PCNs) that can undergo Cu(I)-catalyzed click reactions enable the combination of GdIII magnetic resonance imaging (MRI) contrast agents and an anticancer drug (gemcitabine, GMC) into a single theranostic platform (see picture). The resulting gadolinium(III)-conjugated, GMC-loaded PCNs (GdIII–PCNGMC) exhibit a significantly superior performance in r1 relaxivity, drug uptake, and pH-sensitive drug release. Credit Angewandte Chemie International Edition

Abstract:
The standard approach to cancer therapy today is to mix and match chemotherapy drugs in order to attack tumors in multiple ways. Now, two separate teams of investigators have demonstrated that using nanoparticles to deliver multiple drugs simultaneously can produce a synergistic effect that boosts the cell-killing ability of both drugs.

Nanoparticles Deliver One-Two Therapeutic Punch to Kill Tumor Cells

Bethesda, MD | Posted on December 17th, 2010

In one study, a team of investigators at Northwestern University has shown that they can combine two powerful but extremely toxic anticancer agents - cisplatin and doxorubicin - in one polymer nanoparticle, producing a substantial boost in their ability of the combination to destroy tumors. In addition, the two-in-one nanoparticle reduces the amount of both drugs needed to kill cancer cells, which presumably would reduce the toxic side effects associated with these drugs.

SonBinh Nguyen and Thomas O'Halloran led this study, which was published in the Journal of the American Chemical Society. Dr. O'Halloran is the co-principal investigator of one of 12 Cancer Nanotechnology Platform Partnerships funded by the National Cancer Institute Alliance for Nanotechnology in Cancer. He is also a member of the Northwestern University Center for Cancer Nanotechnology Excellence (CCNE), which is also part of the Alliance for Nanotechnology in Cancer.

Though originally designed to carry arsenic trioxide to solid tumors, the nanoparticles used in this study are proving to be quite versatile in their ability to ferry a wide range of cargos to malignancies. In this study, the investigators wanted to see if delivering two drugs in one nanoparticle offered any advantages of delivering them without the nanoparticle or in separate nanoparticles. The nanoparticles, which the researchers call nanobins, are made by encasing a liposome inside a pH-responsive polymer cage. In this case, doxorubicin is entrapped within the liposome's core, while cisplatin was entrapped in the polymer cage.

In an initial set of experiments, the investigators determined that a 5 to 1 ratio of cisplatin to doxorubicin was the most effective at treating ovarian tumors when the two drugs were combined in the same nanoparticle. When the two drugs were administered at this ratio but with each in its own nanoparticle, the combination was not only less effective at killing malignant cells, but the two drugs appeared to be interfering with each other, a phenomenon often observed in clinical practice. Administering the two drugs in the same nanoparticle ensures that the drugs are hitting their intracellular targets at the same time, which is what likely leads to the synergism observed in this study.

Meanwhile, Mansoor Amiji and Zhenfeng Duan, co-principle investigators of the Cancer Nanotechnology Platform Partnership at Northeastern University, have shown that a different type of polymer nanoparticle can also deliver two anticancer agents simultaneously and as a result can kill cancer cells that have become resistant to drug therapy. In this case, the researchers synthesized biocompatible polymer nanoparticles that entrapped paclitaxel and lonidamine and that targeted the epidermal growth factor receptor (EGFR) that is overexpressed on highly aggressive tumors. When added to tumor cells growing in culture, the nanoparticle containing both drugs was far more effective at killing the drug-resistance cells than when the two drugs were co-administered in separate nanoparticles. The investigators reported their findings in the journal Molecular Pharmaceutics.

In a separate set of experiments, the results of which were published in the journal Angewandte Chemie International Edition, Drs. Nguyen and O'Halloran, joined by Thomas Meade, another member of the Northwestern CCNE, demonstrated that nanobins can also co-deliver a therapeutic and magnetic resonance imaging agent to tumors. In this study, the researchers loaded the anticancer agent gemcitabine into the nanobin's core and added a gadolinium magnetic resonance contrast agent to the nanobin's surface. When added to mouse tumor cells, the nanobins were taken up rapidly and the nanobins were clearly visible in magnetic resonance images. In addition, the nanoparticles released their gemcitabine payload once the nanobins were taken up by the cultured cells.

This work, which is detailed in three papers, was supported in part by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. Abstracts of the papers are available at the journals' websites.

Journal of the American Chemical Society paper -
View abstract here pubs.acs.org/doi/abs/10.1021/ja107333g

Molecular Pharmaceutics paper -
View abstract here pubs.acs.org/doi/abs/10.1021/mp1002653

Angewandte Chemie International Edition paper -
View abstract here tinyurl.com/28yfmcv

####

About NCI Alliance for Nanotechnology in Cancer
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Copyright © NCI Alliance for Nanotechnology in Cancer

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Creating a color printer that uses a colorless, non-toxic ink inspired by nature February 11th, 2016

SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016

Nanoparticle reduces targeted cancer drug's toxicity February 11th, 2016

Cima NanoTech Debuts Large Interactive Touch Screens with European Customers at ISE 2016: For the first time in Europe, Cima NanoTech’s wide range of high performance, projected capacitive touch modules are showcased February 11th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Creating a color printer that uses a colorless, non-toxic ink inspired by nature February 11th, 2016

SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016

Composite Pipe Long Term Testing Facility February 10th, 2016

Scientists take nanoparticle snapshots February 10th, 2016

Possible Futures

Chemical cages: New technique advances synthetic biology February 10th, 2016

New thin film transistor may lead to flexible devices: Researchers engineer an electronics first, opening door to flexible electronics February 10th, 2016

Electron's 1-D metallic surface state observed: A step for the prediction of electronic properties of extremely-fine metal nanowires in next-generation semiconductors February 9th, 2016

A fast solidification process makes material crackle February 8th, 2016

Academic/Education

SUNY Poly and GLOBALFOUNDRIES Announce New $500M R&D Program in Albany To Accelerate Next Generation Chip Technology: Arrival of Second Cutting Edge EUV Lithography Tool Launches New Patterning Center That Will Generate Over 100 New High Tech Jobs at SUNY Poly February 9th, 2016

COD Grad Begins Postdoctoral Fellow at Harvard University: Marsela Jorgolli's Passion for Physics Has Led to a Decade of Academic Research That Continues at Harvard University as a Postdoctoral Fellow February 2nd, 2016

Heriot-Watt's Institute of Photonics & Quantum Sciences uses the Deben Microtest 2 kN tensile stage to characterise ceramics and engineering plastics January 21st, 2016

Multiple uses for the JPK NanoWizard AFM system in the Smart Interfaces in Environmental Nanotechnology Group at the University of Illinois at Urbana-Champaign January 20th, 2016

Nanomedicine

SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016

Nanoparticle reduces targeted cancer drug's toxicity February 11th, 2016

Nanoparticle therapy that uses LDL and fish oil kills liver cancer cells February 9th, 2016

Leading bugs to the death chamber: A kinder face of cholesterol February 8th, 2016

Announcements

Creating a color printer that uses a colorless, non-toxic ink inspired by nature February 11th, 2016

SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016

Nanoparticle reduces targeted cancer drug's toxicity February 11th, 2016

Cima NanoTech Debuts Large Interactive Touch Screens with European Customers at ISE 2016: For the first time in Europe, Cima NanoTech’s wide range of high performance, projected capacitive touch modules are showcased February 11th, 2016

Nanobiotechnology

SLAC X-ray laser turns crystal imperfections into better images of important biomolecules: New method could remove major obstacles to studying structures of complex biological machines February 11th, 2016

Nanoparticle reduces targeted cancer drug's toxicity February 11th, 2016

Chemical cages: New technique advances synthetic biology February 10th, 2016

Nanoparticle therapy that uses LDL and fish oil kills liver cancer cells February 9th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic